Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3613987 | 0.89 | SMN1; SMN2 (0.36) | AAK1SMN1; SMN2NPSR1ALDH1A1LMNA | |
| SCHEMBL3612904 | 0.88 | AAK1 (0.32) | AAK1SMN1; SMN2 | |
| SCHEMBL13077956 | 0.86 | EGLN1 (0.32) | SMN1; SMN2NPSR1 | |
| SCHEMBL3605351 | 0.84 | MAPT (0.37) | SMN1; SMN2NPSR1ALDH1A1LMNAHTT | |
| SCHEMBL535142 | 0.83 | AAK1 (0.31) | AAK1SMN1; SMN2 | |
| SCHEMBL535141 | 0.83 | AAK1 (0.31) | AAK1SMN1; SMN2 | |
| SCHEMBL3617277 | 0.80 | SMN1; SMN2 (0.52) | SMN1; SMN2NPSR1LMNACYP1A2CYP3A4 | |
| SCHEMBL2222286 | 0.79 | LMNA (0.40) | SMN1; SMN2LMNA | |
| SCHEMBL4951293 | 0.78 | ALDH1A1 (0.31) | NPSR1ALDH1A1 | |
| SCHEMBL3728868 | 0.76 | SMN1; SMN2 (0.32) | SMN1; SMN2NPSR1ALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113513-A1 | QUINOLINE DERIVATIVES AS FUNGICIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| EP-2139324-A1 | QUINOLINE DERIVATIVES AS FUNGICIDES | Syngeta Participations AG (CH) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008110355-A1 | QUINOLINE DERIVATIVES AS FUNGICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113513-A1 | QUINOLINE DERIVATIVES AS FUNGICIDES | CYP1A1, CYP4X1, CYP3A7 | AAK1 4095/4885SMN1; SMN2 3466/4885NPSR1 2913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.